CXCR4-based imaging agents

Lauren E. Woodard, Sridhar Nimmagadda

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Chemokine receptor 4 (CXCR4)-chemokine ligand 12 (CXCL12) interactions have been shown to play key roles in cancer cell survival, proliferation, chemotaxis, homing, adhesion, tumor angiogenesis, and resistance to conventional and targeted therapies. Given its extensive involvement in cancer progression, the CXCR4-CXCL12 axis has been considered a therapeutic target. Several inhibitors blocking this signaling cascade are in phase I trials. Because CXCR4 is constitutively expressed in a wide variety of normal tissues, patient stratification and noninvasive monitoring would improve therapeutic outcome and reduce unnecessary toxicities. This review focuses on recent developments in CXCR4-based imaging agents and their potential role in the molecular diagnosis and treatment of cancer.

Original languageEnglish (US)
Pages (from-to)1665-1669
Number of pages5
JournalJournal of Nuclear Medicine
Issue number11
StatePublished - Nov 1 2011


  • Cancer
  • Chemokine
  • Chemokine receptor
  • Metastasis
  • Molecular imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'CXCR4-based imaging agents'. Together they form a unique fingerprint.

Cite this